|Over a week ago|
HTG Molecular Introduces the HTG EdgeSeq Pan B-Cell Lymphoma Panel » 16:0306/1806/18/20
HTG Molecular Diagnostics…
HTG Molecular Diagnostics announced the pre-launch introduction of its new HTG EdgeSeq Pan B-Cell Lymphoma Panel, which is expected to be commercially available for purchase in kit form or as a service in HTG's VERI/O laboratory starting in July 2020. The HTG EdgeSeq Pan B-Cell Lymphoma Panel is a research-use only panel designed to provide molecular characterization of aggressive lymphomas by allowing researchers to measure the expression of genes associated with the aggressive lymphoma transcriptome. Globally, there are nearly 600,000 new cases of lymphoma diagnosed and over 250,000 deaths from the various lymphoma subtypes annually. Correctly diagnosing lymphomas often requires 20 or more immunohistochemical tests, and incorrect subtype classification is common. HTG's new comprehensive HTG EdgeSeq Pan B-Cell Lymphoma Panel is designed to better facilitate identification of lymphoma subgroups addressing this important market.
|Over a month ago|
HTG Molecular signs three new European distributor agreements » 16:0306/1106/11/20
HTG Molecular announced…
HTG Molecular announced the signing of three new European distributor agreements to promote HTG products and services in Nordic and Eastern European Countries with BioNordika in Denmark, Explorea in Czech Republic and ELTA 90 in Bulgaria. "Expanding and strengthening our distribution network into these European markets is another important growth step for HTG," said Jean Claude Gerard, senior VP of European operations. "Working closely with these distributors will improve our ability to reach new customers with our HTG EdgeSeq technology, which we believe will further accelerate our molecular profiling and diagnostic growth opportunities in the region this year."
HTG Molecular case study to be used as marketing, says Cantor Fitzgerald » 15:5806/0406/04/20
Cantor Fitzgerald analyst…
Cantor Fitzgerald analyst Kristen Kluska reiterates an Overweight rating on HTG Molecular with a $1.50 price target after the company posted a case study discussing findings from a comparison of the transcriptional response of SARS-CoV-2 to other respiratory viruses, utilizing RNASeq, a competing product. The analyst understands this will be used as a marketing piece for HTG. Results from the study showed key differences from SARS-CoV-2 with other viruses, which included a strong chemokine transcriptional response and a weak interferon, Kluska tells investors in a research note. While many of HTG's customers work in oncology, this could be an opportunity to work with existing and new customers to discuss the capabilities of the HTG EdgeSeq panels to better understand the virus, adds the analyst.
HTG Molecular says HTG EdgeSeq technology highlighted in posters » 08:1006/0206/02/20
HTG Molecular Diagnostics…
HTG Molecular Diagnostics announced its HTG EdgeSeq technology was highlighted in several posters presented at the American Society of Clinical Oncology 2020 Virtual program. Posters presented at the 2020 Virtual ASCO conference using HTG EdgeSeq technology include: Platform comparison of HTG EdgeSeq and RNA-Seq for gene expression profiling of tumor tissue specimens; Association between immune and tumor gene signatures with response or resistance to tislelizumab monotherapy or in combination with chemotherapy in gastroesophageal adenocarcinoma; Immune- and tumor-intrinsic gene expression profiles of response or resistance to tislelizumab as monotherapy or in combination with chemotherapy in non-small cell lung cancer; Integrated-omics of MRI-visible and -invisible prostate cancer identifies molecular correlations with clinical outcome; Immune-checkpoint genes as predictive biomarkers of trabectedin in advanced soft-tissue sarcoma: A Spanish Group for Research on Sarcomas translational study.
HTG Molecular reports Q1 EPS (8c), consensus (10c) » 16:1405/1305/13/20
Reports Q1 revenue $2.2M,…
Reports Q1 revenue $2.2M, consensus $3.04M. Cash, cash equivalents and short-term available-for-sale securities totaled $32.0M as of March 31, with current liabilities of approximately $8.4M and non-current liabilities of $11.6M. An additional $3.3M of restricted cash was held in connection with a convertible note that is included in current liabilities as of March 31.
HTG Molecular assumed with an Overweight at Cantor Fitzgerald » 07:1005/1105/11/20
Cantor Fitzgerald analyst…
Cantor Fitzgerald analyst Kristen Kluska assumed coverage of HTG Molecular with an Overweight rating with a price target of $1.50, down from $2.00. With all the scientific advancements, it's become apparent that a "one-size-fits-all" approach is not the solution for treating diseases, Kluska tells investors in a research note. While the analyst expects the diagnostics sector to face pressure in 2020 from COVID-19, she thinks that recent momentum could pick up when things normalize.
|Over a quarter ago|
HTG Molecular downgraded to Hold from Buy at Craig-Hallum » 07:3903/2603/26/20
Craig-Hallum analyst Alexander Nowak downgraded HTG Molecular to Hold from Buy with a price target of 70c, down from $2.50. The analyst notes that the recurrent PDP delays, the lack of good news and potentially major COVID-19 impact are "too difficult to look past."
HTG Molecular reports FY19 EPS (51c), consensus (55c) » 16:0503/2503/25/20
Reports Q4 revenue…
Reports Q4 revenue $19.2M, consensus $19.25M. "Growth in our direct revenue in 2019 reflects the consistent efforts of our team, which have resulted in increased adoption of our technology in our core BioPharma and Academic markets," said John Lubniewski, President and CEO of HTG. "While our collaborative development services revenue reflects the reduced activity of our partners as they approached key decision points in 2019, we are no less optimistic about that business and the opportunities that will be available to HTG in this space in the longer term. Our molecular diagnostic development effort, which is being led by the team in our newly opened San Carlos facility, is making tremendous progress, and we believe that the advancements being made there have the potential to transform cancer care."
HTG Molecular announces utilization of EdgeSeq Mouse mRNA tumor response panel » 08:1702/1102/11/20
HTG Molecular highlighted…
HTG Molecular highlighted the HTG EdgeSeq Mouse mRNA tumor response panel as a way to identify endogenous targets of cardiac fibrosis as reported in the September 2019 issue of Nature. In a mouse study, researchers sought to identify the cardiac immune response to fibrosis in mice and provide proof-of-principle for the development of immunotherapeutic drugs for the treatment of cardiac disease. Using the HTG EdgeSeq Mouse mRNA Tumor Response Panel, researchers assessed the expression levels of 1,659 inflammatory and immune genes and found that 22 genes were differentially expressed between normal and CAR T-cell treated mice.
HTG Molecular announces publication on miRNA Whole Transcriptome Assay » 08:0902/0502/05/20
HTG Molecular Diagnostics…
HTG Molecular Diagnostics highlighted the reproducibility of the HTG EdgeSeq miRNA Whole Transcriptome Assay as reported in a peer-reviewed paper in the December 2019 issue of Cell Reports. In a study designed and conducted by Paula M. Godoy et al, four miRNA profiling methods were compared using biofluids with both synthetic and biological micro-RNA samples. The paper, titled "Comparison of Reproducibility, Accuracy, Sensitivity, and Specificity of miRNA Quantification Platforms," concluded that the HTG EdgeSeq platform using the miRNA WTA was the most reproducible and had the least detection bias when compared to the other technologies tested. "Our miRNA WTA product can deliver results in as few as 36 hours and leverages the sensitivity and dynamic range of next generation sequencing (NGS)-based detection while preserving precious sample as it requires no additional concentration steps," said Mike Hrubiak, Vice President of Marketing at HTG. "This is another example of our EdgeSeq platform technology being validated in peer-reviewed prestigious scientific journals."